Confusion about the Appropriate Use of Erythropoiesis-Stimulating Agents in Patients Undergoing Maintenance Dialysis

Seminars in Dialysis

Volumn 23, Issue 5, 2010, Pages 486-491

  Winkelmayer, Wolfgang C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; DRUG EFFECT; ERYTHROPOIESIS; EVIDENCE BASED MEDICINE; HUMAN; RENAL REPLACEMENT THERAPY;

ANEMIA; ERYTHROPOIESIS; ERYTHROPOIETIN; EVIDENCE-BASED MEDICINE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 78049450025     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00768.x     Document Type: Article

References (18)

1. Shahidi NT: Androgens and erythropoiesis. N Engl J Med 289:72-80, 1973
2. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
3. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
4. Powe NR, Griffiths RI, De Lissovoy G, Anderson GF, Watson AJ, Greer JW, Herbert RJ, Eggers PW, Milam RA, Whelton PK: Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA 268:1434-1440, 1992
5. United States Renal Data System: USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease and Chronic Kidney Disease in the United States, Chapter 5: Clinical Indicators and Preventive Health. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009: 259-268.
6. United States Renal Data System: USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease and Chronic Kidney Disease in the United States, Chapter 11: Costs of ESRD. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009: 335-342
7. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
8. Canadian Erythropoietin Study Group. Association: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 300:573-578, 1990
9. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071-2084, 2006
10. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085-2098, 2006
11. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, De Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019-2032, 2009
12. MEDCAC Meetings: 3/24/2010 - Erythopoiesis Stimulating Agents (ESA) in Anemia Related to Kidney Disease., accessed July 29, 2010
13. Anonymous. NCA: Tracking Sheet for Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on Dialysis (CAG-00413N)., accessed July 29, 2010
14. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesis-stimulating agents--time for a reevaluation. N Engl J Med 362:189-192, 2010
15. Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K: Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 52:727-736, 2008
16. Agarwal R: Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate. Clin J Am Soc Nephrol 5:1340-1346, 2010
17. Singh AK: ESAs in dialysis patients: are you a hedgehog or a fox? J Am Soc Nephrol 21:543-546, 2010
18. Department of Health and Human Services, Centers for Medicare and Medicaid Services, 42 CFR Parts 410, 413 and 414. Medicare Program; End-Stage Renal Disease Prospective Payment System; Final Rule and Proposed Rule. II.M. Anemia Management and Dialysis Adequacy Measures. Federal Register, 75 (155), 49182-49190